Mon, Sep 22, 2014, 8:33 AM EDT - U.S. Markets open in 57 mins.


% | $
Quotes you view appear here for quick access.

MannKind Corp. Message Board

  • fisk007 fisk007 Mar 11, 2013 8:22 PM Flag

    Gilead market cap up $35 Billion since purchase of VRUS for $11 Billion

    Read that Seeking Alpha article very closely.

    What was seen as an extremely high price of $11 Billion to acquire Pharmasset when Gilead had a $32 Billion Market Cap is now seen as a brilliant move by Gilead. They are being rewarded handsomely by the Street with a nearly $70 Billion market cap 16 months after the deal.

    Have a feeling the monumental size of the diabetes opportunity will force some hands here (Lilly, Merck, Sanfoli) to either put up or get shut out of what may be a $15 to $25 Billion global annual revenue opportunity within 3 to 5 years.

    MNKD must be looking really attractive to these big players.

    Wonder how much data MNKD has shared with potential suitors ( as did VRUS before a bidding war broke out for them prior to Gilead winning).

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Will a Lilly, Sanofi or Merck go after MNKD in a $6 to $10 Billion Acquisition?

    • Gilead Sciences Inc. GILD agreed to acquire drug developer Pharmasset Inc. for nearly $11 billion, placing a big bet on the market for new treatments for hepatitis C infections.

      The offer represents a nearly 89% premium to Pharmasset's closing price Friday and an impressive return for a stock that traded below $10 as recently as January 2010. Pharmasset shares soared 85% to $134.14 in Monday afternoon trading on the Nasdaq Stock Market.

      From Wall Street Journal Article November 2011

      Note: Gilead Market Cap was $29.9 Billion at the time it acquired Pharmasset for $11 Billion. Gilead spent 37% of their $29.9 Billion Market Cap to acquire the potential Pharmasset Hep C drug - PRE FDA Approval.

      Lilly, Merck and Sanofi are the rumored potential interested parties in MNKD. The average Market Cap of the three is $105 Billion.

      They most certainly could make an acquisition in the $10 to $20 Billion Range.

      Especially if it will help them double their market cap like the Gilead acquisition of Pharmasset.

    • With nearly 30% of the public float traded over the last 2 days - it would seem there may indeed be ample interest in acquiring or partnering with MNKD by the likes of Lilly, Sanofi, Merck or possibly a completely unknown potential partner.

    • my hunch has always been MRK.

      ...and I think all info MNKD has is being shared w/ whomever the prospective partner is

6.20-0.03(-0.48%)Sep 19 4:15 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.